A comparison among three maximal mathematical models of the glucose-insulin system
Open accessThe DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index; 17 of the 68 sources its claims cite were checked for support.
Abstract
The most well-known and widely used mathematical representations of the physiology of a diabetic individual are the Sorensen and Hovorka models as well as the UVAPadova Simulator. While the Hovorka model and the UVAPadova Simulator only describe the glucose metabolism of a subject with type 1 diabetes, the Sorensen model was formulated to simulate the behaviour of both normal and diabetic individuals. The UVAPadova model is the most known model, accepted by the FDA, with a high level of complexity. The Hovorka model is the simplest of the three models, well documented and used primarily for the development of control algorithms. The Sorensen model is the most complete, even though some modifications were required both to the model equations (adding useful compartments for modelling subcutaneous insulin delivery) and to the parameter values. In the present work several simulated experiments, such as IVGTTs and OGTTs, were used as tools to compare the three formulations in order to establish to what extent increasing complexity translates into richer and more correct physiological behaviour. All the equations and parameters used for carrying out the simulations are provided.
Overview
CoChat Summary
TL;DR
This paper compares three maximal glucose-insulin models—Sorensen, Hovorka, and UVAPadova S2017—across simulated IVGTT and OGTT protocols and an OGTT fit to normal-subject data. It finds that the original Sorensen model underestimates diabetic hyperglycemia unless insulin-sensitivity parameters are modified, after which all three models behave similarly, though Sorensen uniquely captures the post-hypoglycemic rebound.
Key findings
- In an in-silico OGTT plus insulin bolus, the original Sorensen model reached a maximum glycemia of 10 mM versus 18 mM for Hovorka and UVAPadova, and returned to baseline in about 300 min, roughly half the time of the other two models.
- After modifying Sorensen parameters—e.g., FPIC 0.150→0.240, FLIC 0.400→0.459, peripheral venous insulin volume 0.740→2.442, and insulin-dependent glucose utilization parameters decreased about tenfold—its predictions became comparable to Hovorka and UVAPadova.
- Fitting to normal-subject OGTT data, Sorensen gave the best fit and was the only model predicting the rebound around minute 200; estimated insulin boluses were 56387.7 pmol (~8 IU) for Sorensen, 2361 mU (~2.3 IU) for Hovorka, and 849 pmol/kg (~8 IU) for UVAPadova. UVAPadova required 10 free parameters versus 4 for Sorensen and 3 for Hovorka, and all UVAPadova free-parameter CVs were >100%.
- In three successive OGTTs in one day, Sorensen reproduced the same glycemic pattern each time; UVAPadova drove glucose progressively lower (below 2 mM), while Hovorka predicted lower glucose in the second and third OGTTs but never below 3 mM.
Methods
- Four in-silico experiments were simulated: IVGTT (0.5 g/kg glucose over 3 min plus basal insulin 6.67 mU/min), IVGTT plus 1000 mU insulin bolus, OGTT (100 g glucose over 1 min) plus basal insulin, and OGTT plus basal insulin plus 1000 mU bolus; initial steady state was glucose 5 mmol/L with basal insulin 6.67 mU/min.
- Models compared were the Sorensen model (revised with gastrointestinal tract and subcutaneous insulin compartments, pancreatic insulin secretion removed for T1DM), the Hovorka model, and the UVAPadova S2017 model; all equations and parameters used are provided.
- For OGTT fitting, weighted least squares was applied to observed glucose concentrations from a normal individual (Sorensen’s PhD thesis) with 100 g glucose, estimating bolus insulin and selected parameters; these estimates were then used to simulate three OGTTs in one day.
Limitations
- Stated: the Sorensen T1DM adaptation assumes diabetic physiology is otherwise the same as normal apart from absent insulin production, so it omits diabetic abnormalities; no actual diabetic-subject perturbation data were available, so it cannot be determined which model is physiologically more credible; OGTT fitting used normal-subject data because OGTT is not standard in diabetic patients.
- Stated: UVAPadova has missing parameter values and some equations described only qualitatively (kp1 and kir were kept constant); from purely in-silico experiments, definitive conclusions cannot be drawn.
- Evident: Sorensen parameter changes were trial-and-error adjustments to match the other models rather than estimates from diabetic data; UVAPadova free parameters all had CV >100%, indicating poor identifiability; the paper also notes that Hovorka and UVAPadova EGP formulations can predict negative EGP at high insulin.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
9 Valid · 1 Not valid · 18 Not checked · 67 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The implemented version of the Sorensen model derives from the equations presented in his original PhD thesis [20], with the corrections introduced in [28] and modified to account for both (possible) subcutaneous administration of insulin and for the reduced insulin-sensitivity, which would be expected in a diabetic patient with respect to a normal individual [1].”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Introduction
What the sources say
- Not matchedcites [20] JT Sorensen, 1985, A Physiologic Model of Glucose Metabolism in Man and Its Use to Design and Improved Insulin Therapies for Diabetes, Massachussets Institute of Technology
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [28] S Panunzi, 2020, A revised Sorensen model: Simulating glycemic and insulinemic response to oral and intra-venous glucose load, PLOS ONE sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Not matchedcites [1] C Guyton, 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While the Hovorka model and the UVAPadova Simulator only describe the glucose metabolism of a subject with type 1 diabetes, the Sorensen model was formulated to simulate the behaviour of both normal and diabetic individuals.”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Abstract
What the sources say
- Not checked — no full text of the sourcecites [17] R Hovorka, 2002, Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT, Am J Physiol Endocrinol Metab source
- Not checked — no full text of the sourcecites [18] R Hovorka, 2004, Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes, Institute of Physics Publishing source
- Not checked — no full text of the sourcecites [19] R Hovorka, 2011, Closed-loop insulin delivery from bench to clinical practice, Nature Reviews Endocrinology source
- Not checked — no full text of the sourcecites [22] C Dalla Man, 2007, Meal Simulation Model of the Glucose-Insulin System, IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING source
- Partly supportedcites [23] C Dalla Man, 2014, The UVAPadova Type 1 Diabetes Simulator: New Features, Journal of Diabetes Science and Technology sourceExperimental — accuracy not yet measured
The Abstract and the S2008 section describe the UVA/PADOVA simulator as modeling glucose regulation in virtual subjects with type 1 diabetes. The S2008 section also describes insulin kinetics, and the Abstract describes glucagon kinetics, so the simulator is not limited to glucose processes alone. Our copy lists a Hovorka paper in the References but does not establish the claim about the Hovorka model. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [24] R Visentin, 2018, The UVAPadova Type I Diabetes Simulator Goes From Single Meal to Single Day, Journal of Diabetes Science and Technology source
- Partly supportedcites [25] C Dalla Man, 2007, GIM, Simulation Software of Meal Glucose–Insulin Model, Journal of Diabetes Science and Technology sourceExperimental — accuracy not yet measured
The References list a Hovorka study of glucose control in subjects with type 1 diabetes, but that does not establish that the Hovorka model describes only type 1 diabetes. The paper does not identify a UVAPadova Simulator or establish the same restriction for it. Its Introduction and Methods instead say that the software presented here, GIM, simulates normal, type 2 diabetic, and type 1 diabetic subjects. (LLM, conf=0.76)
- Partly supportedcites [26] R Visentin, 2016, Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator, Diabetes Technology & Therapeutics sourceExperimental — accuracy not yet measured
The Introduction and Research Design and Methods describe the UVA/Padova simulator as modeling virtual patients with type 1 diabetes. The Methods specify glucose–insulin–glucagon dynamics, rather than glucose alone. Our copy does not address the Hovorka model or the comparison with the Sorensen model (pages unavailable). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [27] R Visentin, 2016, One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Towards a Single-Day UVAPadova Type 1 Diabetes Simulator, IEEE Trans Biomed Eng source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The parameters of the Hovorka and UVA/Padova models are instead indicated for a diabetic individual, but the more compact formulation of the Hovorka model requires fewer modifications to obtain a good fit.”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Results > OGTT model fitting
What the sources say
- Not checked — no full text of the sourcecites [17] R Hovorka, 2002, Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT, Am J Physiol Endocrinol Metab source
- Not checked — no full text of the sourcecites [18] R Hovorka, 2004, Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes, Institute of Physics Publishing source
- Not checked — no full text of the sourcecites [19] R Hovorka, 2011, Closed-loop insulin delivery from bench to clinical practice, Nature Reviews Endocrinology source
- Not checked — no full text of the sourcecites [22] C Dalla Man, 2007, Meal Simulation Model of the Glucose-Insulin System, IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING source
- Not checked — no full text of the sourcecites [24] R Visentin, 2018, The UVAPadova Type I Diabetes Simulator Goes From Single Meal to Single Day, Journal of Diabetes Science and Technology source
- Partly supportedcites [25] C Dalla Man, 2007, GIM, Simulation Software of Meal Glucose–Insulin Model, Journal of Diabetes Science and Technology sourceExperimental — accuracy not yet measured
The Introduction (pp. 323–330; page not specified in our copy) describes GIM settings for simulating type 1 and type 2 diabetic subjects, which supports the diabetic-simulation aspect of the claim. It does not identify GIM as the UVA/Padova model or describe parameters of the Hovorka model; Hovorka appears only in the references. Nor does it compare how many modifications the models require. (LLM, conf=0.78)
- Partly supportedcites [26] R Visentin, 2016, Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator, Diabetes Technology & Therapeutics sourceExperimental — accuracy not yet measured
In Research Design and Methods (page unavailable), the paper says the UVA/Padova type 1 diabetes simulator assigns subject-specific parameters drawn to reflect variability in the type 1 diabetes population. It does not discuss the Hovorka model, so it supports the claim about UVA/Padova parameters but not the claim about Hovorka parameters. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [27] R Visentin, 2016, One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Towards a Single-Day UVAPadova Type 1 Diabetes Simulator, IEEE Trans Biomed Eng source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“To make the three models comparable, two subcutaneous compartments were therefore added to the revised Sorensen model (which already includes the gastro-intestinal compartment [28]).”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Methods > The Sorensen T1DM model
What the sources say
- Supportedcites [28] S Panunzi, 2020, A revised Sorensen model: Simulating glycemic and insulinemic response to oral and intra-venous glucose load, PLOS ONE source
The citation is attached to the parenthetical claim that the revised Sorensen model already includes a gastrointestinal compartment, not to the citing authors’ addition of two subcutaneous compartments. The Methods (Sorensen model analysis) describe the added gastrointestinal tract as an input to the model’s glucose-gut compartment. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Sorensen model appears to be the only one capable of reproducing exactly the same glycemic pattern in the three sub-experiments, with a return to pre-bolus conditions after each OGTT.”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Results > OGTT model fitting
hedgedstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
44 more claims
Create a free account to see all 95 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A comparison among three maximal mathematical models of the glucose-insulin system > Methods > Comparison among models simulations
“All the above experiments were performed by setting the initial conditions (which also represent the steady state conditions) at a glucose concentration of 5 mmol/L with a basal insulin delivery of 6.67 mU/min for each model considered.”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Methods > The Hovorka model
“| u basal | mU/min | Continuous rate of subcutaneous insulin infusion into compartment 1 | 6.68 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A comparison among three maximal mathematical models of the glucose-insulin system > Discussion
“In the IVGTT experiment without insulin bolus administration (Fig 4)”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Results
“Figure: Fig 4 Blood glucose concentrations from the Hovorka (solid line), Sorensen (dashed line) and UVAPadova (dotted line) models, during the in-silico IVGTT experiment in conjunction with an insulin bolus.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A comparison among three maximal mathematical models of the glucose-insulin system > Methods > The Sorensen T1DM model
“| τ S | /min | Time constant for insulin absorption | 55 |”
§ A comparison among three maximal mathematical models of the glucose-insulin system > Results > OGTT model fitting
“| τS(min) | 55 | 39.538 | 1.898 | 4.78% |”
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085 · cited 2×
“However, Hinshaw [30] demonstrated that there was no evidence of differences between breakfast and dinner in terms of glucose disappearance in Type 1 diabetic subjects.”
BackgroundQuantitative estimation of insulin sensitivity.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.6.e667 · Cited by 1,874
Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes
Hovorka, R., Canonico, V., Chassin, L. J., Haueter, U., Massi-Benedetti, M., Federici, M. O., Pieber, T. R., Schaller, H. C., Schaupp, L., Vering, T., et al. (2004) · Physiological Measurement · doi:10.1088/0967-3334/25/4/010 · Cited by 1,274 · cited 1×
“• The Hovorka model [18] is the simplest among the three analysed models; it describes the relationship between glucose and insulin in subjects with in Type 1 diabetes: therefore, like the UVAPadova model, it does not present a description of the secretion and the release of endogenous insulin.”
MethodType 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Meal Simulation Model of the Glucose-Insulin System
Dalla Man, C., Rizza, R. A., & Cobelli, C. (2007) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2007.893506 · Cited by 955 · cited 1×
“1: Meal Simulation Model of the Glucose-Insulin System (2007) [22] 2: GIM, Simulation Software of Meal Glucose–Insulin Model (2007) [25] 3: One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Towards a Single-Day UVA/Padova Type 1 Diabetes Simulator (2016) [27] 4: The UVA/Padova Type I Diabetes Simulator Goes From S…”
MethodThe UVA/PADOVA Type 1 Diabetes Simulator: New Features
Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813514502 · Cited by 791 · cited 4×
“The equation from UVAPadova S2017 [24] is replaced by that in UVAPadova (2014) [23], because reported with an error.”
BackgroundMethodInfluentialIn Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647 · cited 2×
“exercise and weight loss, the first treatment choice for most patients with Type 2 diabetes [8], individuals with Type 1 diabetes mellitus require exogenous insulin administrations to supply the lack of endogenous pancreatic insulin production.”
BackgroundArtificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms
Doyle, F. J., Huyett, L. M., Lee, J. B., Zisser, H. C., & Dassau, E. (2014) · Diabetes Care · doi:10.2337/dc13-2108 · Cited by 394
Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT
Hovorka, R., Shojaee-Moradie, F., Carroll, P. V., Chassin, L. J., Gowrie, I. J., Jackson, N. C., Tudor, R. S., Umpleby, A. M., & Jones, R. H. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00304.2001 · Cited by 393
Closed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342
The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
Visentin, R., Campos-Náñez, E., Schiavon, M., Lv, D., Vettoretti, M., Breton, M., Kovatchev, B. P., Dalla Man, C., & Cobelli, C. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757747 · Cited by 280 · cited 12×
“Since their formulations have not been reported in the original work, in the present study we assumed piecewise constant functions for kp3 and Vmx from the inspection of Fig 2 in [24], whereas kp1 was set to a constant value.”
MethodInfluentialGlobal Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)
KAISER, A. B., ZHANG, N., & DER PLUIJM, W. V. (2018) · Diabetes · doi:10.2337/db18-202-lb · Cited by 263
GIM, Simulation Software of Meal Glucose–Insulin Model
Dalla Man, C., Raimondo, D. M., Rizza, R. A., & Cobelli, C. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100303 · Cited by 253
Closed-Loop Control of Blood Glucose
(2007) · Lecture Notes in Control and Information Sciences · doi:10.1007/978-3-540-74031-5 · Cited by 184 · cited 2×
“analysed are the Hovorka model [17–19], the Sorensen model [20, 21] and the UVAPadova model [22–27].”
MethodThe artificial pancreas: current status and future prospects in the management of diabetes
Peyser, T., Dassau, E., Breton, M., & Skyler, J. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12431 · Cited by 169
Diurnal Pattern of Insulin Action in Type 1 Diabetes
Hinshaw, L., Dalla Man, C., Nandy, D. K., Saad, A., Bharucha, A. E., Levine, J. A., Rizza, R. A., Basu, R., Carter, R. E., Cobelli, C., et al. (2013) · Diabetes · doi:10.2337/db12-1759 · Cited by 125
Run-to-run control of blood glucose concentrations for people with type 1 diabetes mellitus
Owens, C., Zisser, H., Jovanovic, L., Srinivasan, B., Bonvin, D., & Doyle, F. J. (2006) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2006.872818 · Cited by 122
Visentin, R., Man, C. D., & Cobelli, C. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2535241 · Cited by 86 · cited 1×
“1: Meal Simulation Model of the Glucose-Insulin System (2007) [22] 2: GIM, Simulation Software of Meal Glucose–Insulin Model (2007) [25] 3: One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Towards a Single-Day UVA/Padova Type 1 Diabetes Simulator (2016) [27] 4: The UVA/Padova Type I Diabetes Simulator Goes From S…”
MethodInduced L2-norm minimization of glucose–insulin system for Type I diabetic patients
Kovács, L., Benyó, B. I., Bokor, J., & Benyó, Z. (2010) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2010.06.019 · Cited by 69
Closed-loop Control of Blood Glucose Levels in Critically Ill Patients
Chee, F., Fernando, T. L., & van Heerden, P. V. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000306 · Cited by 55
Closed-loop insulin delivery – what lies between where we are and where we are going?
Steil, G. M., & Rebrin, K. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.353 · Cited by 39
Visentin, R., Giegerich, C., Jäger, R., Dahmen, R., Boss, A., Grant, M., Dalla Man, C., Cobelli, C., & Klabunde, T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0128 · Cited by 36 · cited 3×
“1: Meal Simulation Model of the Glucose-Insulin System (2007) [22] 2: GIM, Simulation Software of Meal Glucose–Insulin Model (2007) [25] 3: One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Towards a Single-Day UVA/Padova Type 1 Diabetes Simulator (2016) [27] 4: The UVA/Padova Type I Diabetes Simulator Goes From S…”
BackgroundMethodInfluentialPanunzi, S., Pompa, M., Borri, A., Piemonte, V., & De Gaetano, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237215 · Cited by 21 · cited 4×
“The implemented version of the Sorensen model derives from the equations presented in his original PhD thesis [20], with the corrections introduced in [28] and modified to account for both (possible) subcutaneous administration of insulin and for the reduced insulin-sensitivity, which would be expected in a diabetic p…”
MethodInfluentialSelf-citationDatabase of virtual objects to be used in psychological research
Popic, D., Pacozzi, S. G., & Martarelli, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238041 · Cited by 15
Lv, D., Kulkarni, S. D., Chan, A., Keith, S., Pettis, R. J., Kovatchev, B. P., Farhy, L. S., & Breton, M. D. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815573864 · Cited by 12 · cited 1×
“The subcutaneous insulin sub-model is described in [25], while the intra-dermal model appears in [29] and the inhaled model is presented in [26].”
Background
Research works printed but not linked: 5
- C Guyton, 2006, Textbook of Medical Physiology Eleventh Edition
- WHO, 2016, Gobal report on diabetes
- HHS, 2020, National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States
- JT Sorensen, 1985, A Physiologic Model of Glucose Metabolism in Man and Its Use to Design and Improved Insulin Therapies for Diabetes, Massachussets Institute of Technology
- L Hinshaw, 2013, Pathogenesis of NIDDM. A balanced overview, Diabetes, 62, 2223
Cited by
Chinese diabetes datasets for data-driven machine learning
Zhao, Q., Zhu, J., Shen, X., Lin, C., Zhang, Y., Liang, Y., Cao, B., Li, J., Liu, X., Rao, W., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-01940-7 · Cited by 123
“Virtual diabetes simulators were studied in tasks such as glycemic events identification, BG control 15 and predictions 14,16–18 .”
MethodMughal, I. S., Patané, L., & Caponetto, R. (2024) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2024.100937 · Cited by 46
Viroonluecha, P., Egea-López, E., & Santa, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274608 · Cited by 31
Mathematical modelling of glucose dynamics
Huard, B., & Kirkham, G. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100379 · Cited by 26
“The model provides predictions comparable to the UVA-Padova and the Hovorka model in in silico simulations [60].”
MethodDietrich, J. W., Dasgupta, R., Anoop, S., Jebasingh, F., Kurian, M. E., Inbakumari, M., Boehm, B. O., & Thomas, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-22531-3 · Cited by 16
Metadata
- Authors
- Pompa, M., Panunzi, S., Borri, A., & De Gaetano, A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- National Research Council (IT)
- Corresponding author
- Pompa, Marcello
- Panunzi, Simona
- Borri, Alessandro
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-09-27
- Volume
- 16
- Issue
- 9
- Pages
- e0257789
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8476045
- OpenAlex
- W3202301434
- Cited by
- 24
- References
- 31
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 3
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-insulin system, mathematical model, Hovorka model, type 1 diabetes, model comparison, model complexity, subcutaneous insulin administration, intravenous glucose tolerance test, oral glucose tolerance test
- MeSH terms
- Computer Simulation, Diabetes Mellitus, Glucose, Humans, Insulin, Models, Biological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.